Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Psychiatry. 2008 Feb;192(2):135-43. doi: 10.1192/bjp.bp.107.041301.

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.

Author information

  • 1Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. m.tohen@lilly.com

Abstract

BACKGROUND:

Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania.

AIMS:

To assess the efficacy and safety of olanzapine plus carbamazepine in mixed and manic bipolar episodes.

METHOD:

Randomised, double-blind, 6-week trial of olanzapine (10-30 mg/day) plus carbamazepine (400-1200 mg/day; n=58) v. placebo plus carbamazepine (n=60) followed by open-label, 20-week olanzapine (10-30 mg/day) plus carbamazepine (400-1200 mg/day, n=86), with change in manic symptoms as main outcome measure. Safety and pharmacokinetics were also evaluated.

RESULTS:

There were no significant differences (baseline to endpoint) in efficacy measures between treatment groups, but at 6 weeks triglyceride levels were significantly higher (P=0.008) and potentially clinically significant weight gain (>or=7%) occurred more frequently (24.6% v. 3.4%, P=0.002) in the combined olanzapine and carbamazepine group. Carbamazepine reduced olanzapine concentrations but olanzapine had no effect on carbamazepine concentrations.

CONCLUSIONS:

The combination of olanzapine and carbamazepine did not have superior efficacy to carbamazepine alone. The increases in weight and triglycerides observed during combination treatment are a matter of concern.

PMID:
18245032
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk